{"id":7208,"date":"2025-05-29T11:10:48","date_gmt":"2025-05-29T08:10:48","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7208"},"modified":"2025-05-29T11:10:48","modified_gmt":"2025-05-29T08:10:48","slug":"first-in-human-data-on-ttvr-device-shows-promising-results","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/first-in-human-data-on-ttvr-device-shows-promising-results\/","title":{"rendered":"First-in-Human Data on TTVR Device Shows Promising Results"},"content":{"rendered":"
First-in-Human Data on TTVR Device Shows Promising Results<\/div>\n
Date: May 23, 2025 | Source: EuroPCR 2025 in oParis.<\/div>\n
1. Device Overview:<\/span><\/div>\n
\u2022 TriCares GmbH presented first-in-human data on its Topaz transcatheter tricuspid valve replacement (TTVR) system during EuroPCR 2025 in oParis.<\/span><\/div>\n
\u2022 The self-expanding two-stent valve prosthesis is delivered through femoral or transjugular access to treat tricuspid regurgitation (TR).<\/span><\/div>\n
2. Study Findings:<\/span><\/div>\n
\u2022 Among the first 20 patients treated, TR was significantly reduced in all cases.<\/span><\/div>\n
\u2022 No patients required permanent pacemakers, and the average procedure time was about 35 minutes.<\/span><\/div>\n
\u2022 So far, 60 Topaz implants have been performed under clinical oversight globally.<\/span><\/div>\n
3. Clinical Indications for TTVR:<\/span><\/div>\n
\u2022 TTVR is considered for patients with moderate to severe tricuspid regurgitation who are:<\/span><\/div>\n
\u2022 Symptomatic, especially with signs of right heart failure (e.g., fatigue, edema).<\/span><\/div>\n
\u2022 At high surgical risk or not eligible for open-heart surgery.<\/span><\/div>\n
\u2022 Experiencing progressive right ventricular dysfunction or worsening quality of life.<\/span><\/div>\n
\u2022 Topaz and similar devices offer a minimally invasive alternative for this complex and often undertreated condition.<\/span><\/div>\n
4. Device-Specific Insights:<\/span><\/div>\n
\u2022 The Topaz system includes a catheter-based delivery method and a two-stent valve.<\/span><\/div>\n
\u2022 It remains investigational and has not yet received FDA or CE mark approval.<\/span><\/div>\n
5. Clinical Outlook:<\/span><\/div>\n
\u2022 TriCares reports performance comparable to other TR therapies, with promising early safety and efficacy signals.<\/span><\/div>\n
\u2022 The company is continuing its clinical trials in Europe and the U.S.<\/span><\/div>\n
6. Expert & Industry Commentary:<\/span><\/div>\n
\u2022 Dr. Julien Dreyfus (France) presented the data at EuroPCR.<\/span><\/div>\n
\u2022 TriCares CEO Ahmed Elmouelhi praised clinical teams and confirmed plans for further optimization.<\/span><\/div>\n
EuroPCR 2025 Presentation Details:<\/div>\n
\u2022 Session: Tricuspid hotline: new devices<\/span><\/div>\n
\u2022 Presenter: Dr. Julien Dreyfus, Centre Cardiologique du Nord, France<\/span><\/div>\n
\u2022 Date\/Time: Thursday, 22 May 2025, 08:30 \u2013 09:30<\/span><\/div>\n
\u2022 Late-Breaking Trials \u2013 EuroPCR 2025 https:\/\/www.pcronline.com\/Courses\/EuroPCR\/Programme\/Late-Breaking-Trials<\/a><\/span><\/div>\n","protected":false},"excerpt":{"rendered":"

First-in-Human Data on TTVR Device Shows Promising Results Date: May 23, 2025 | Source: EuroPCR 2025 in oParis. 1. Device Overview: \u2022 TriCares GmbH presented first-in-human data on its Topaz transcatheter tricuspid valve replacement (TTVR) system during EuroPCR 2025 in oParis. \u2022 The self-expanding two-stent valve prosthesis is delivered through femoral or transjugular access to […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7208","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7208","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7208"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7208\/revisions"}],"predecessor-version":[{"id":7209,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7208\/revisions\/7209"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7208"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7208"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}